An international specialty pharma company

Meda is a leading international specialty pharma company with a focus on marketing and product development in late clinical phase. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries.

The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Exchange in Stockholm.

	New PDUFA goal date for ezogabine in the U.S.2010-08-31 08:20 - Pressrelease - pdf
	Meda acquires Alaven, a US specialty pharma company2010-08-30 13:39 - Pressrelease - pdf
	Ezogabine receives positive vote from FDA advisory committee2010-08-12 08:35 - Pressrelease - pdf
	Meda AB (publ) – Interim report, January–June 20102010-08-04 08:00 - Interim report - pdf
	Meda receives one-time payment of 45 MEUR2010-07-23 08:00 - Pressrelease - pdf
	Meda acquires exclusive rights to new treatment of actinic keratosis2010-05-12 11:30 - Pressrelease - pdf
	Onsolis approved in Canada2010-05-10 13:58 - Pressrelease - pdf
	Meda acquires exclusive rights to flupirtine for fibromyalgia, a potential USD billion indication2010-05-07 09:45 - Pressrelease - pdf
	Meda AB (publ) AGM bulletin2010-05-05 19:38 - Minutes of annual general meeting - pdf
	Meda AB (publ) – Interim report, January-March 20102010-05-05 08:00 - Quarterly report - pdf

More news »

Priority therapy areas are
respiratory, cardiology, pain and inflammation, dermatology and CNS.

Read more »

Meda's shares are traded on Nasdaq OMX Nordic Exchange in Stockholm under Large Cap.

Meda Annual Report 2009 »
(PDF document, opens in new window)

Financial information and press releases »